EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 676 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Selpercatinib Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC MOST POPULAR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... October 24, 2025 Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors? July 27, 2021 FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer May 3, 2024 FDA Approves Acalabrutinib with Venetoclax for CLL or SLL March 4, 2026 Load more HOT NEWS What Are Clinical Practice Guidelines and How Do They Impact Care... FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns
